Skip to main content
CYPH
NASDAQ Life Sciences

Cypherpunk Q2 Profit Masks Unremediated Material Weakness and Heavy Dilution Overhang

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.71
Mkt Cap
$72.396M
52W Low
$0.232
52W High
$3.7
52W Position info
206% above low
Off High info
81% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

CYPH has more than doubled off its 52-week low of $0.232 on light trading volume (0.2× avg).

Summary

Cypherpunk's Q2 profit was driven by a non-cash Zcash revaluation gain, while the 10-Q discloses an unremediated material weakness, heavy dilution from ATM sales and warrants, and a going-concern reliance on equity financing.


Key Events · Earnings and Guidance · CYPH

  • Non-Cash Profit Masks Operating Loss

    Q2 net income of $39.4M was entirely due to a $46M unrealized gain on the embedded derivative from Zcash holdings. Operating loss was $4.7M, and H1 operating loss was $9.5M.

  • Material Weakness Remains Unremediated

    Management concluded disclosure controls and internal control over financial reporting were not effective as of June 30, 2026, due to a previously identified material weakness that has not been remediated.

  • Heavy Dilution from ATM Sales

    The company sold 22.2M shares under its $200M Cantor ATM program in H1 2026, raising $19.2M net. Shares outstanding rose from 83.9M to 107.8M — a 28% increase in six months.

  • Massive Warrant Overhang

    158.7M shares are issuable upon warrant exercise, including 80.8M pre-funded warrants at $0.001 and 76M common warrants at $0.5335. Fully diluted share count could exceed 266M.


Analysis · CYPH · Life Sciences

A surprise Q2 profit of $39.4 million at Cypherpunk Technologies came entirely from a non-cash $46 million mark-to-market increase on its Zcash holdings — not from operations. The 10-Q reveals an unremediated material weakness in internal controls, a going-concern evaluation that leans on a $200 million ATM facility, and a massive overhang: 158.7 million shares issuable from warrants, plus 16.6 million unvested RSUs. With only $7.6 million in cash and a Nasdaq deficiency notice for sub-$1 trading, the company is funding operations by selling shares into the market — 22.2 million shares sold in H1 2026 alone. The headline profit obscures a precarious financial position.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CYPH was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.4M. The 52-week trading range was $0.23 to $3.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CYPH - Latest Insights

CYPH
Aug 19, 2026, 6:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $1.94 info
Change: +$0.8662 (+81%) info
Market Cap: $215.529M info
CYPH
Aug 19, 2026, 6:54 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $1.94 info
Change: +$0.8662 (+81%) info
Market Cap: $215.529M info
CYPH
Aug 18, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7269
Real-time Price: $1.94 info
Change: +$1.21 (+167%) info
Market Cap: $215.529M info
CYPH
Aug 12, 2026, 7:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.710
Real-time Price: $1.94 info
Change: +$1.23 (+173%) info
Market Cap: $215.529M info
CYPH
Aug 12, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.710
Real-time Price: $1.94 info
Change: +$1.23 (+173%) info
Market Cap: $215.529M info